The therapeutic benefits of inhibiting IL-25 in conditions, such as allergic lung inflammation, where airway remodeling is a key event, suggest that IL-25 is an important mediator of tissue regeneration and consequently fibrosis in conditions, such as asthma. This evidence concerns the gene IL25 and asthma.